Evidence map›Paper›PMID 21357860›Full record

Trial reportJournal of the American Dental Association (1939)2011

The effect of subantimicrobial-dose-doxycycline periodontal therapy on serum biomarkers of systemic inflammation: a randomized, double-masked, placebo-controlled clinical trial.

Jeffrey B Payne, Lorne M Golub, Julie A Stoner, Hsi-Ming Lee, Richard A Reinhardt, Timo Sorsa, Marvin J Slepian

Registry-linked trialOpen access · greenAbstract readMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of the American Dental Association (1939), 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00066027 (Low-Dose Doxycycline Effects on Osteopenic Bone Loss), which is not on this map. Cited by 45 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed, 8 pooled it
7.9field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00066027 phase3completednot on this map

Low-Dose Doxycycline Effects on Osteopenic Bone Loss

TypeinterventionalSponsorUniversity of NebraskaRan2002 to 2005Enrolled128ConditionsPeriodontitisArms20 mg doxycycline hyclate, Placebo
3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 8 syntheses or guidelines pooled it, 82 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Trial
  10. Trial
  11. Subantimicrobial-dose doxycycline treatment increases serum cholesterol efflux capacity from macrophages.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2013
    Trial
  12. Trial
  13. Review
  14. Article
  15. Central Nervous System Antimicrobial Exposure and Proposed Dosing for Anthrax Meningitis.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024
    Article
  16. Review
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 6 institutions in 2 countries.

Jeffrey B PayneDepartment of Surgical Specialties, College of Dentistry, University of Nebraska Medical Center, Lincoln, Neb. 68583-0740, USA. jbpayne@unmc.edu
Lorne M Golub
Julie A Stoner
Hsi-Ming Lee
Richard A Reinhardt
Timo Sorsa
Marvin J Slepian
Stony Brook University · USNebraska Medical Center · USUniversity of Arizona · USUniversity of Helsinki · FIUniversity of Nebraska Medical Center · USUniversity of Oklahoma · US

Funding

LOW-DOSE DOXYCYCLINE EFFECTS ON OSTEOPENIC BONE LOSSR01DE012872 · NIDCR · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI PAYNE, JEFFREY BRUCE · 2001 to 2007
$3.0M
NIDCR NIH HHS R01 DE012872NIDCR NIH HHS R01DE012872
6 · The paper itself

Abstract

backgroundPeriodontitis has been reported to be associated with coronary artery disease (CAD). Research is needed to determine if therapies that improve periodontal health also reduce systemic measures of inflammation associated with both diseases.

methodsThe study registrar randomly assigned 128 eligible postmenopausal women with chronic periodontitis to a twice-daily regimen of subantimicrobial-dose-doxycycline (SDD) or placebo tablets for two years as an adjunct to periodontal maintenance therapy. Through a supplement to the main trial, in which they investigated alveolar bone and clinical attachment level changes, the authors assayed inflammatory mediators and lipid profiles in baseline, one-year and two-year serum samples. The authors analyzed the data by using generalized estimating equations.

resultsIn the intent-to-treat analysis across two years, SDD treatment reduced median high-sensitivity C-reactive protein (hs-CRP) by 18 percent (primary outcome; P = .02) and reduced serum matrix metalloproteinase (MMP)-9 (92 kilodalton gelatinase; difference in mean scanning units, -28.44; P < .001), with no significant effect on serum lipids. However, in women more than five years postmenopausal, SDD elevated the level of high-density lipoprotein (HDL) cholesterol (difference in means [milligrams per deciliter], 5.99; P = .01).

conclusionA two-year SDD regimen in postmenopausal women significantly reduced the serum inflammatory biomarkers hs-CRP and MMP-9 and, among women more than five years postmenopausal, increased the HDL cholesterol level. CLINICAL IMPLICATIONS: SDD significantly reduced the systemic inflammatory biomarkers hs-CRP and MMP-9. More research is needed to determine whether SDD has a role in managing the care of patients at risk of developing CAD.

Indexed as

Anti-Bacterial AgentsBone Diseases, MetabolicCholesterol, HDLChronic PeriodontitisCoronary DiseaseC-Reactive ProteinDouble-Blind MethodDoxycyclineFemaleHumansInflammation MediatorsMatrix Metalloproteinase 9Middle AgedAnti-Bacterial AgentsCholesterol, HDLC-Reactive ProteinDoxycyclineInflammation MediatorsMatrix Metalloproteinase 9

Identifiers

PMID21357860
PMCPMC3077029
OpenAlexW9720479

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.